PMID- 9577661
OWN - NLM
STAT- MEDLINE
DCOM- 19980701
LR  - 20061115
IS  - 0009-918X (Print)
IS  - 0009-918X (Linking)
VI  - 37
IP  - 12
DP  - 1997 Dec
TI  - [Recent advances of immune therapies for demyelinating neuropathies].
PG  - 1111-2
AB  - Most of acquired demyelinating neuropathies are caused by immune-mediated 
      processes. Therefore, we can treat these neuropathies to control underlying 
      immune abnormality. We review the recent therapies and show possible strategies 
      in the future. (1) Recent therapies Guillain-Barre syndrome should be treated 
      quickly and intensively in the first week of the disease with plasmapheresis 
      (PP). Intravenous immunoglobulin (IVIG) is as effective as PP. IVIG is under 
      phase 3 clinical trial in Japan. Chronic inflammatory demyelinating 
      polyneuropathy (CIDP) is treated with corticosteroids, PP or IVIG. 
      Corticosteroids or PP is the first choice. For severe or resistant cases, 
      combined therapy or immunosuppressants, such as cyclophosphamide pulse therapy, 
      should be considered. Polyneuropathy with IgM-MGUS (monoclonal gammopathies of 
      undetermined significance) is treated with PP, immunosuppressants or these 
      combinations to decrease serum IgM, especially for cases with anti-MAG antibody, 
      because the autoantibody induces demyelination by itself. (2) Future strategies 
      Immunopathogenesis may differ among cases with Guillain-Barre syndrome or CIDP. 
      The best therapy will be chosen individually, according to appropriate 
      immunologic tests. In CIDP, immunomodulation therapies, that are similar ones in 
      multiple sclerosis, will be considered to maintain improvement.
FAU - Ito, H
AU  - Ito H
AD  - Department of Neurology, Kitasato University East Hospital.
FAU - Saito, T
AU  - Saito T
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Rinsho Shinkeigaku
JT  - Rinsho shinkeigaku = Clinical neurology
JID - 0417466
SB  - IM
MH  - Demyelinating Diseases/*therapy
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Polyradiculoneuropathy/*therapy
EDAT- 1998/05/13 00:00
MHDA- 1998/05/13 00:01
CRDT- 1998/05/13 00:00
PHST- 1998/05/13 00:00 [pubmed]
PHST- 1998/05/13 00:01 [medline]
PHST- 1998/05/13 00:00 [entrez]
PST - ppublish
SO  - Rinsho Shinkeigaku. 1997 Dec;37(12):1111-2.